Login to Your Account



Pharma: Clinic Roundup


Thursday, May 10, 2012
• Sunovion Pharmaceuticals Inc., of Marlborough, Mass., reported results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to Latuda (lurasidone HCl).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription